Whitepapers/App Notes/Posters

Technical bulletin: Nitrosamines: Questioning the current analytical approach

Posted: 27 May 2021 | | No comments yet

We look at the challenges posed in regards to nitrosamine testing methodologies and the way in which to move forward to ensure safer drug products.

In recent years, multiple drug products (DPs) have been recalled following the discovery of nitrosamine impurities. Consequently, regulators and the pharmaceutical industry are working hard to identify sources of nitrosamine impurities.

The latest US Food and Drug Administration (FDA) guidance from 2020 lists at least seven potential root causes, while the most recent guidance by the European Medical Agency (EMA) lists eleven. The variety in the possible root causes makes accurate risk assessment a challenging proposition. In this white paper, we look at the challenges posed in regards to testing methodologies and the way in which to move forward to ensure safer DPs.












    To read this technical bulletin in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of SGS Life Science

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend